Aktis Oncology, Inc. Statistics
Want to see AKTS full AI Analyst Report?
Aktis Oncology, Inc. (AKTS) Stock Statistics & Valuation Metrics
Total Valuation
Aktis Oncology, Inc. has a market cap or net worth of $970.56M. The enterprise value is $1.28B.
- Market Cap
- $970.56M
- Enterprise Value
- $1.28B
Share Statistics
Aktis Oncology, Inc. has 53,746,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 53,746,670
- Owned by Insiders
- 47.33%
- Owned by Institutions
- 17.59%
Financial Efficiency
Aktis Oncology, Inc.’s return on equity (ROE) is 0.44 and return on invested capital (ROIC) is -31.79%.
- Return on Equity (ROE)
- 0.44
- Return on Assets (ROA)
- -0.24
- Return on Invested Capital (ROIC)
- -31.79%
- Return on Capital Employed (ROCE)
- -0.32
- Revenue Per Employee
- 82.24K
- Profits Per Employee
- -806.72K
- Employee Count
- 79
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Aktis Oncology, Inc. is -16.23. Aktis Oncology, Inc.’s PEG ratio is 2.35.
- PE Ratio
- -16.23
- PS Ratio
- 91.04
- PB Ratio
- 1.94
- Price to FCF
- -10.83
- Price to Operating Cash Flow
- -12.52
- PEG Ratio
- 2.35
Income Statement
In the last 12 months, Aktis Oncology, Inc. had revenue of 6.50M and earned -63.73M in profits. Earnings per share was -1.19.
- Revenue
- 6.50M
- Gross Profit
- 6.50M
- Operating Income
- -74.68M
- Pretax Income
- -63.73M
- Net Income
- -63.73M
- EBITDA
- -61.40M
- Earnings Per Share (EPS)
- -1.19
Cash Flow
In the last 12 months, operating cash flow was -75.29M and capital expenditures -9.27M, giving a free cash flow of -84.57M billion.
- Operating Cash Flow
- -75.29M
- Free Cash Flow
- -84.57M
- Free Cash Flow per Share
- -1.53
Dividends & Yields
Aktis Oncology, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.23%
- Earnings Yield
- -7.75%
Stock Price Statistics
- Beta
- 2.23
- 52-Week Price Change
- -22.10%
- 50-Day Moving Average
- 19.52
- 200-Day Moving Average
- 20.93
- Relative Strength Index (RSI)
- 53.65
- Average Volume (3m)
- 388.45K
Important Dates
Aktis Oncology, Inc. upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Aktis Oncology, Inc. as a current ratio of 7.37, with Debt / Equity ratio of -7.90%
- Current Ratio
- 7.37
- Quick Ratio
- 7.37
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.43
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Aktis Oncology, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Aktis Oncology, Inc. EV to EBITDA ratio is -10.87, with an EV/FCF ratio of -9.99.
- EV to Sales
- 84.01
- EV to EBITDA
- -10.87
- EV to Free Cash Flow
- -9.99
- EV to Operating Cash Flow
- -11.22
Balance Sheet
Aktis Oncology, Inc. has $517.32M in cash and marketable securities with $11.24M in debt, giving a net cash position of $506.08M billion.
- Cash & Marketable Securities
- $517.32M
- Total Debt
- $11.24M
- Net Cash
- $506.08M
- Net Cash Per Share
- $9.42
- Tangible Book Value Per Share
- $8.76
Margins
Gross margin is 84.78%, with operating margin of -866.63%, and net profit margin of -727.04%.
- Gross Margin
- 84.78%
- Operating Margin
- -866.63%
- Pretax Margin
- -727.04%
- Net Profit Margin
- -727.04%
- EBITDA Margin
- -772.77%
- EBIT Margin
- -800.84%
Analyst Forecast
The average price target for Aktis Oncology, Inc. is $35.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $35.80
- Price Target Upside
- 105.16% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 4
- AI Score
- 43
